Metropolis Healthcare Ltd.

NSE: METROPOLIS | BSE: 542650 | ISIN: INE112L01020 | Industry: Healthcare Services
| Momentum Trap

1876.50
-2.29%
ICICI Securities Limited
Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests. In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25.
Number of FII/FPI investors increased from 171 to 177 in Sep 2025 qtr.
More from Metropolis Healthcare Ltd.
Recommended